Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study-Reference-Cited by-同舟云学术

Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study

Published:2014-03-20 Issue:8 Volume:93 Page:1413-1420
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Tatarelli Caterina,Piccioni Anna Lina,Maurillo Luca,Naso Virginia,Battistini Roberta,D’Andrea Mariella,Criscuolo Marianna,Nobile Carolina,Villivà Nicoletta,Mancini Stefano,Neri Benedetta,Breccia Massimo,Fenu Susanna,Buccisano Francesco,Voso Maria Teresa,Latagliata Roberto,Aloe Spiriti Maria Antonietta

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-014-2053-9.pdf

Reference26 articles.

1. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112:45–52

2. Cogle CR, Craig BM, Rollison DE, List AF (2011) Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117(26):7121–7125, Epub 2011 Apr 29

3. Ma X (2012) Epidemiology of myelodysplastic syndrome. Am J Med 125(7 Suppl):S2–S5

4. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23:7594–7603

5. Oliva EN (2011) A review of anemia as a cardiovascular risk factor in patients with myelodisplastic syndrome. Am J Blood Res 1(2):160–166

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes;Journal of Clinical Medicine;2024-05-04

2. Epoetin alfa biosimilar (HX575): A review of 15 years’ post-approval clinical experience;Critical Reviews in Oncology/Hematology;2023-01

3. Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes;Journal of Clinical Medicine;2022-03-17

4. Replica a la carta al editor titulada: «Efectividad y seguridad de la eritropoyetina alfa en el paciente (ortopédico) mayor de 65 años»;Revista Española de Geriatría y Gerontología;2019-07

5. Efectividad y seguridad de la eritropoyetina alfa en el paciente (ortopédico) mayor de 65 años;Revista Española de Geriatría y Gerontología;2019-03